The role of endogenous testosterone in relationship with low- and intermediate-risk prostate cancer: a systematic review.
- Author:
Antonio Benito PORCARO
1
;
Emanuele SERAFIN
;
Davide BRUSA
;
Sonia COSTANTINO
;
Claudio BRANCELLI
;
Maria Angela CERRUTO
;
Alessandro ANTONELLI
Author Information
- Publication Type:Journal Article
- MeSH: Humans; Male; Prostatic Neoplasms/metabolism*; Testosterone/metabolism*; Risk Factors; Neoplasm Grading; Tumor Burden
- From: Asian Journal of Andrology 2024;26(6):569-574
- CountryChina
- Language:English
- Abstract: An enduring debate in research revolves around the association between elevated endogenous testosterone levels and prostate cancer. This systematic review is intended to assess the present understanding of the role of endogenous testosterone in the diagnosis and treatment of low- and intermediate-risk prostate cancer. Our search strategy was the following: (endogenous testosterone) AND (((low risk) OR (intermediate risk)) AND ((diagnosis) OR (treatment))) AND (prostate cancer); that was applied to PubMed, Web of Science, and Scopus databases to identify pertinent articles. Two investigators performed an independent selection following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The preliminary investigation detected 105 records, and 81 records remained after eliminating duplicates. Following the review of titles and abstracts, 71 articles were excluded. A comprehensive examination of the full text was conducted for 10 articles, excluding 3 of them. After revising the references of eligible articles, other 3 articles were included. We finally identified 10 suitable studies, including three main topics: (1) association between endogenous testosterone and European Association of Urology (EAU) risk classes; (2) association between endogenous testosterone density and the tumor load; and (3) association of endogenous testosterone with tumor upgrading and tumor upstaging. Actual literature about the impact of endogenous testosterone on low- and intermediate-risk prostate cancer is not numerous, but appears to be still conflicting. More investigations are needed to increase the consistency of the literature's results.
